| Species |
Human |
| Protein Construction |
SEMA7A (Gln45-Ala648)
Accession # O75326-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
69.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-75 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Semaphorin7A (Sema7A) plays an important role in the immunoregulation of the brain.Sema7A is upregulated in the epileptic brain and plays a potential role in the regulation of seizure activity in PTZ-kindled epileptic rats, which may be related to neuroinflammation. Sema7A promotes the inflammatory cytokines TNF-α and IL-6 as well as the growth of mossy fibers through the ERK pathway, suggesting that Sema7A may promote seizures by increasing neuroinflammation and activating pathological neural circuits. Sema7A plays a critical role in epilepsy and could be a potential therapeutic target for this neurological disorder. |
| Synonyms |
Semaphorin-7A; Semaphorin-K1; Semaphorin-L; Sema L; CD108; CD108MGC126696; CDw108; H-SEMA-K1; H-Sema-L; JMH; MGC126692; Sema7A; SEMAK1; SEMAL |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
